Compared side by side
Retatrutide vs VK2735: how they differ
The short answer
VK2735 switches on two receptors, GLP-1 and GIP, the pair tirzepatide works through; retatrutide adds a third, glucagon, whose arm adds calorie burn (shown in mice). Neither is approved: both are weekly shots in phase 3, and VK2735 is also being tested as a daily tablet. Retatrutide’s top dose averaged about 25–28% weight loss at 80 weeks in phase 3, and VK2735 took off about 9% to 15% in its 13-week phase 2 trial.
Side by side
| Compared | Retatrutide | VK2735 |
|---|---|---|
| Category | Metabolic & GLP-1 | Metabolic & GLP-1 |
| Also known as | LY3437943 | VK-2735, VK 2735 |
| What it is | The first triple agonist to reach phase 3: it activates GLP-1, GIP and glucagon receptors at once, and the glucagon arm adds extra calorie burn (shown in mice). | A weekly GLP-1 and GIP dual agonist from Viking Therapeutics, the same two-receptor approach as tirzepatide, also being tested as a daily tablet. |
| How it works | Triple GIP/GLP-1/glucagon receptor agonist. Produces large weight loss through appetite suppression and improved metabolic function; the glucagon arm adds energy expenditure, shown so far in mice. Its trials step the dose up every 4 weeks because GI side effects rise with the dose; in phase 2 they were milder with a 2 mg start than a 4 mg one. | Once-weekly peptide that switches on both the GLP-1 and the GIP receptors, the same pair tirzepatide works through. A side chain stretches its half-life to about 7 to 10 days in people, long enough for weekly shots. The idea is the one tirzepatide proved: two incretin signals that curb appetite and food intake together. Viking also makes it as a daily tablet, the same molecule by mouth. Investigational, in phase 3 since June 2025. |
| Commonly reported | Appetite suppression even stronger than tirzepatide, GI side effects after each step-up, and a higher resting heart rate. Its top dose averaged about 25–28% weight loss at 80 weeks in phase 3; it isn't approved yet. | In trials, nausea and other GI effects early on, fading as the dose holds. It is in phase 3 and not approved anywhere. |
| Studied range | Research range: 1–12 mg, starting dose 2 mg. Studied in research — not a recommendation. | Research range: 2.5–17.5 mg, starting dose 2.5 mg. Studied in research — not a recommendation. |
| How often | Weekly | Weekly |
| Half-life | ~6 days (measured in early trials in people) | ~9 days (measured in people: 170–250 hours after single doses, Viking phase 1, 2023) |
| Route | SubQ injection | SubQ injection |
| Typical run | Phase 3 trials use continuous dosing. Community mirrors this — long-term with slow titration. | Used continuously, once weekly, in its trials: 13 weeks in phase 2 and 78 weeks in phase 3. In Viking's maintenance study, people who switched after 21 weekly doses to a shot every other week or once a month kept most of their loss over the next 12 weeks; on placebo they kept about 61%. |
| Evidence | Established: clinical trials or FDA-approved use exists | Moderate: animal studies + some human data |
| Common side effects | Nausea, vomiting, diarrhea, constipation, decreased appetite, fatigue, abdominal pain | Nausea, constipation, diarrhea, vomiting, acid reflux, fatigue, dry mouth |
- Category
- RetatrutideMetabolic & GLP-1
- VK2735Metabolic & GLP-1
- Also known as
- RetatrutideLY3437943
- VK2735VK-2735, VK 2735
- What it is
- RetatrutideThe first triple agonist to reach phase 3: it activates GLP-1, GIP and glucagon receptors at once, and the glucagon arm adds extra calorie burn (shown in mice).
- VK2735A weekly GLP-1 and GIP dual agonist from Viking Therapeutics, the same two-receptor approach as tirzepatide, also being tested as a daily tablet.
- How it works
- RetatrutideTriple GIP/GLP-1/glucagon receptor agonist. Produces large weight loss through appetite suppression and improved metabolic function; the glucagon arm adds energy expenditure, shown so far in mice. Its trials step the dose up every 4 weeks because GI side effects rise with the dose; in phase 2 they were milder with a 2 mg start than a 4 mg one.
- VK2735Once-weekly peptide that switches on both the GLP-1 and the GIP receptors, the same pair tirzepatide works through. A side chain stretches its half-life to about 7 to 10 days in people, long enough for weekly shots. The idea is the one tirzepatide proved: two incretin signals that curb appetite and food intake together. Viking also makes it as a daily tablet, the same molecule by mouth. Investigational, in phase 3 since June 2025.
- Commonly reported
- RetatrutideAppetite suppression even stronger than tirzepatide, GI side effects after each step-up, and a higher resting heart rate. Its top dose averaged about 25–28% weight loss at 80 weeks in phase 3; it isn't approved yet.
- VK2735In trials, nausea and other GI effects early on, fading as the dose holds. It is in phase 3 and not approved anywhere.
- Studied range
- RetatrutideResearch range: 1–12 mg, starting dose 2 mg. Studied in research — not a recommendation.
- VK2735Research range: 2.5–17.5 mg, starting dose 2.5 mg. Studied in research — not a recommendation.
- How often
- RetatrutideWeekly
- VK2735Weekly
- Half-life
- Retatrutide~6 days (measured in early trials in people)
- VK2735~9 days (measured in people: 170–250 hours after single doses, Viking phase 1, 2023)
- Route
- RetatrutideSubQ injection
- VK2735SubQ injection
- Typical run
- RetatrutidePhase 3 trials use continuous dosing. Community mirrors this — long-term with slow titration.
- VK2735Used continuously, once weekly, in its trials: 13 weeks in phase 2 and 78 weeks in phase 3. In Viking's maintenance study, people who switched after 21 weekly doses to a shot every other week or once a month kept most of their loss over the next 12 weeks; on placebo they kept about 61%.
- Evidence
- RetatrutideEstablished: clinical trials or FDA-approved use exists
- VK2735Moderate: animal studies + some human data
- Common side effects
- RetatrutideNausea, vomiting, diarrhea, constipation, decreased appetite, fatigue, abdominal pain
- VK2735Nausea, constipation, diarrhea, vomiting, acid reflux, fatigue, dry mouth
Typical run: Community practice — opinions vary. Not a clinical recommendation.

Model. Individual results vary.
Week by week
Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.
Retatrutide
- Day 1–28 · 2 mg Triple-agonist is kicking in
- Day 29–84 · 4 mg Dose-response steepens
- Day 60+ · 9 mg Watch for dysesthesia at higher doses
- Day 84+ This is a maintenance medication, not a course
- Day 85–168 · 8 mg Higher steps: strong satiety
- Day 169–336 No plateau yet at week 48
- Day 337–476 Phase 3 territory: the headline numbers
VK2735
- Day 1–21 · 2.5 mg Low start, first weeks
- Day 22–91 The first 13 weeks
- Day 22–546 · 7.5 mg The lowest phase 3 dose
- Day 43–546 · 12.5 mg The middle phase 3 dose
- Day 43–546 · 17.5 mg The top phase 3 dose
- Day 150+ Holding the loss on fewer shots
Questions people ask
How long do retatrutide and VK2735 last?
The half-life of retatrutide is ~6 days (measured in early trials in people). The half-life of VK2735 is ~9 days (measured in people: 170–250 hours after single doses, Viking phase 1, 2023).
How often are retatrutide and VK2735 taken?
Retatrutide: weekly. Route: SubQ injection. VK2735: weekly. Route: SubQ injection.
How are retatrutide and VK2735 dosed in research?
The research range for retatrutide is 1–12 mg, with a 2 mg starting dose. The research range for VK2735 is 2.5–17.5 mg, with a 2.5 mg starting dose. Studied in research — not a recommendation.
What are the common side effects of retatrutide and VK2735?
For retatrutide, the library lists: nausea, vomiting, diarrhea, constipation, decreased appetite, fatigue, abdominal pain. For VK2735: nausea, constipation, diarrhea, vomiting, acid reflux, fatigue, dry mouth.